INVESTOR RELATIONS

---

Rejuvenalt

Regenerative Medicine for a Post-Pharma Era

Big Pharma Has Failed Modern Health

• $1.4 trillion global pharmaceutical market is dominated by symptom management and synthetic interventions
   
• 66% of Americans are on prescription drugs — most for chronic conditions
   
• Rising backlash: side effects, polypharmacy, and corporate profiteering
   
• No regenerative solutions — only maintenance
   

A New Era of Regenerative, Holistic Medicine

• Consumers are seeking clean, natural, and side-effect-free alternatives
   
• $300B global supplement market — projected to surpass $500B by 2030
   
• Health optimization, longevity, biohacking, and personalized wellness are exploding
   
• Rejuvenalt is uniquely positioned at the intersection of science, regeneration, and natural innovation
   

To Lead the Post-Pharma Movement

Rejuvenalt’s mission is to create and scale scientifically validated regenerative medicines and supplements that:

• Eliminate chronic dependency
   
• Heal the body at a cellular level
   
• Leverage nature’s intelligence with modern science
   
• Disrupt the synthetic drug model with organic innovation
   

Core Therapeutic Categories

• Cellregen-X – Mitochondrial restoration & energy
   
• NeuroVitalis – Cognitive repair & nootropic balance
   
• GutBiome+ – Microbiome & immune optimization
   
• InflammRestore – Systemic inflammation & pain control
   
• BioShield-7 – Cellular detox & immune resilience
   
• RegenFast – Full-spectrum nutrient recovery
   
• HormoBalance – Hormonal, adrenal & endocrine regulation
   

What Makes Rejuvenalt Unstoppable

• Proprietary science-backed formulations
   
• Doctor and practitioner co-development
   
• Bioavailable delivery systems (liposomal, nanoemulsion)
   
• No synthetic fillers, preservatives, or pharma derivatives
   
• Root-cause targeting, not symptom suppression
   
• Integrated education + product ecosystem
   

Omnichannel, Scalable, Community-Driven

• Direct-to-Consumer (eCommerce, subscription)
   
• Strategic influencer and practitioner partnerships
   
• Clinical research & functional medicine endorsement
   
• Global distribution via integrative health networks
   
• Thought leadership via media, podcast, longevity events
   

Early Validation and Forward Momentum

• Formulas developed with leading biochemists & naturopaths
   
• Beta customer group: 92% reorder rate
   
• Exclusive manufacturing, partnerships with 3 functional clinics & 2 health influencers
   
• Website and brand launch Q4 2025
   
• Scientific advisory board formation in progress
   

3-Year Forecast (Conservative Base Case)

• Year 1: $100M revenue | Net Margin: 22%
   
• Year 2: $350M revenue | Net Margin: 35%
   
• Year 3: $920M revenue | Net Margin: 42%
   
• Subscription revenue expected to exceed 60% by Year 3
   

Seeking $25M Seed Round

To fund:

• Inventory and production scale-up
   
• Clinical testing and lab certification
   
• Digital platform and eCommerce development
   
• Brand ambassador program
   
• Regulatory and IP protections
   

Offering:

• SAFE or Convertible Note terms
   
• Valuation cap: $12M pre-money
   
• Early investor incentives and equity bonus tier